Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses how PARP inhibitors play a large role in maintenance therapy in first-line settings for ovarian cancer and the importance of homologous recombination deficiency (HRD) testing in the clinic. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.